# PTC Therapeutics, Inc.: overview

PTCT · Nasdaq · CIK 1070081 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ptct.md) · [Financials](/companies/ptct/financials.md) · [Filings](/companies/ptct/filings.md) · [Insiders](/companies/ptct/insiders.md)

Latest reported revenue: [$357.8m](/filings/0001104659-26-120223.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-120223).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [213 d](/filings/0001104659-26-017575.md) | [1,176](/filings/0001070081-26-000012.md) | [179](/filings/0001070081-26-000017.md) | [211](/filings/0001104659-26-120223.md) | [165 d](/filings/0001104659-26-017575.md) | [273](/filings/0001070081-26-000012.md) | [361](/filings/0001070081-26-000017.md) | [358](/filings/0001104659-26-120223.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(76.2%) d](/filings/0001104659-26-017575.md) | [82.5%](/filings/0001070081-26-000012.md) | [(19.5%)](/filings/0001070081-26-000017.md) | [1.4%](/filings/0001104659-26-120223.md) | [(43.3%) d](/filings/0001104659-26-017575.md) | [16.5%](/filings/0001070081-26-000012.md) | [41.3%](/filings/0001070081-26-000017.md) | [7.0%](/filings/0001104659-26-120223.md) |
| Net margin | % | [(30.9%) d](/filings/0001104659-26-017575.md) | [73.7%](/filings/0001070081-26-000012.md) | [(36.3%)](/filings/0001070081-26-000017.md) | [7.5%](/filings/0001104659-26-120223.md) | [(82.0%) d](/filings/0001104659-26-017575.md) | [(1.0%)](/filings/0001070081-26-000012.md) | [23.2%](/filings/0001070081-26-000017.md) | [(14.4%)](/filings/0001104659-26-120223.md) |
| Diluted EPS | $ per share | not reported | [10.04](/filings/0001070081-26-000012.md) | [(0.83)](/filings/0001070081-26-000017.md) | [0.20](/filings/0001104659-26-120223.md) | not reported | [(0.03)](/filings/0001070081-26-000012.md) | [0.92](/filings/0001070081-26-000017.md) | [(0.62)](/filings/0001104659-26-120223.md) |
| Free cash flow | $m | [(33.8) d](/filings/0001104659-26-017575.md) | [868](/filings/0001070081-26-000012.md) | [(59.6) d](/filings/0001070081-26-000017.md) | [(69.8) d](/filings/0001104659-26-120223.md) | [(36.6) d](/filings/0001104659-26-017575.md) | [(60.2)](/filings/0001070081-26-000012.md) | [127 d](/filings/0001070081-26-000017.md) | [(28.0) d](/filings/0001104659-26-120223.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [539](/filings/0001558370-24-002196.md) | [699](/filings/0001070081-25-000012.md) | [938](/filings/0001104659-26-017575.md) | [807](/filings/0001104659-26-017575.md) | [1,731](/filings/0001104659-26-017575.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(69.5%)](/filings/0001558370-24-002196.md) | [(64.0%)](/filings/0001070081-25-000012.md) | [(46.9%)](/filings/0001104659-26-017575.md) | [(37.5%)](/filings/0001104659-26-017575.md) | [50.1%](/filings/0001104659-26-017575.md) |
| Net margin | % | [(97.3%)](/filings/0001558370-24-002196.md) | [(80.0%)](/filings/0001070081-25-000012.md) | [(66.8%)](/filings/0001104659-26-017575.md) | [(45.0%)](/filings/0001104659-26-017575.md) | [39.4%](/filings/0001104659-26-017575.md) |
| Diluted EPS | $ per share | [(7.43)](/filings/0001558370-24-002196.md) | [(7.79)](/filings/0001070081-25-000012.md) | [(8.37)](/filings/0001104659-26-017575.md) | [(4.73)](/filings/0001104659-26-017575.md) | [7.78](/filings/0001104659-26-017575.md) |
| Free cash flow | $m | [(280)](/filings/0001558370-24-002196.md) | [(389)](/filings/0001070081-25-000012.md) | [(187)](/filings/0001104659-26-017575.md) | [(114)](/filings/0001104659-26-017575.md) | [702](/filings/0001104659-26-017575.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ptct/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.14bn | 13,964,554 |  | Added +1,015,837 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $631.9m | 7,746,415 |  | Unchanged |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $590.2m | 7,236,402 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $490.0m | 7,193,433 |  | Not compared |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $402.0m | 4,928,111 |  | Added +123,517 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $375.1m | 4,598,952 |  | Added +252,433 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $336.7m | 4,128,273 |  | Added +185,663 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $305.0m | 3,739,127 |  | Added +62,871 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $180.1m | 2,207,376 |  | Reduced −2,578 |
| [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $176.7m | 2,165,846 |  | Reduced −860,117 |

## Recent filings

[All 1,312 filings](/companies/ptct/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:31 ET | [10-Q](/filings/0001104659-26-120223.md) | Quarterly report, period 2026-09-30 | 0001104659-26-120223 |
| 2026-10-29 | 16:10 ET | [8-K](/filings/0001104659-26-120200.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-120200 |
| 2026-09-21 | 16:34 ET | [8-K](/filings/0001070081-26-000023.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001070081-26-000023 |
| 2026-08-28 | 16:06 ET | [8-K](/filings/0001070081-26-000019.md) | 1.01 Entry into a material agreement | 0001070081-26-000019 |
| 2026-08-13 | 07:00 ET | [8-K](/filings/0001104659-26-095424.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-095424 |
| 2026-07-30 | 16:32 ET | [10-Q](/filings/0001070081-26-000017.md) | Quarterly report, period 2026-06-30 | 0001070081-26-000017 |
| 2026-07-30 | 16:05 ET | [8-K](/filings/0001070081-26-000016.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001070081-26-000016 |
| 2026-06-18 | 16:14 ET | [8-K](/filings/0001104659-26-075731.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-075731 |
| 2026-06-16 | 07:00 ET | [8-K](/filings/0001104659-26-074292.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-074292 |
| 2026-06-09 | 17:15 ET | [8-K](/filings/0001104659-26-071916.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-071916 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-017575.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/330bbb57-ca78-45c4-828d-368440dcfc28)

## About the filer

- CIK: 1070081
- Tickers: PTCT
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:45 ET. No prices; not investment advice.